Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Gynecology

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 110 articles:
HTML format



Single Articles


    April 2021
  1. SCHOUTROP E, El-Serafi I, Poiret T, Zhao Y, et al
    Mesothelin-specific CAR T cells target ovarian cancer.
    Cancer Res. 2021 Apr 1. pii: 0008-5472.CAN-20-2701.
    PubMed     Abstract available


    February 2021
  2. BELUR NAGARAJ A, Knarr M, Sekhar S, Connor RS, et al
    The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer.
    Cancer Res. 2021 Feb 11. pii: 0008-5472.CAN-20-2041.
    PubMed     Abstract available


    January 2021
  3. KHELIL M, Griffin H, Bleeker MCG, Steenbergen RDM, et al
    Delta-like ligand-Notch1 signalling is selectively modulated by HPV16 E6 to promote squamous cell proliferation and correlates with cervical cancer prognosis.
    Cancer Res. 2021 Jan 26. pii: 0008-5472.CAN-20-1996.
    PubMed     Abstract available


  4. SHRESTHA R, Llaurado Fernandez M, Dawson A, Hoenisch J, et al
    Multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability.
    Cancer Res. 2021 Jan 13. pii: 0008-5472.CAN-20-2222.
    PubMed     Abstract available


    December 2020
  5. KARLSSON T, Johansson T, Hoglund J, Ek WE, et al
    Time-dependent effects of oral contraceptive use on breast, ovarian and endometrial cancers.
    Cancer Res. 2020 Dec 17. pii: 0008-5472.CAN-20-2476.
    PubMed     Abstract available


    November 2020
  6. SOOTOME H, Fujita H, Ito K, Ochiiwa H, et al
    Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Cancer Res. 2020;80:4986-4997.
    PubMed     Abstract available


  7. DRERUP JM, Deng Y, Pandeswara SL, Padron AS, et al
    CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
    Cancer Res. 2020;80:5063-5075.
    PubMed     Abstract available


  8. WANG Y, Zhao G, Condello S, Huang H, et al
    Frizzled-7 Identifies Platinum Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
    Cancer Res. 2020 Nov 10. pii: 0008-5472.CAN-20-1488.
    PubMed     Abstract available


  9. WAN C, Keany MP, Dong H, Al-Alem LF, et al
    Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high grade serous ovarian cancer.
    Cancer Res. 2020 Nov 6. pii: 0008-5472.CAN-20-1674.
    PubMed     Abstract available


    October 2020
  10. PARASHAR D, Nair B, Geethadevi A, George J, et al
    Peritoneal Spread of Ovarian Cancer harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
    Cancer Res. 2020 Oct 21. pii: 0008-5472.CAN-19-3717.
    PubMed     Abstract available


  11. SHEN YA, Hong J, Asaka R, Asaka S, et al
    Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Cancer Res. 2020;80:4514-4526.
    PubMed     Abstract available


    September 2020
  12. TAMURA N, Shaikh N, Muliaditan D, Soliman TN, et al
    Specific mechanisms of chromosomal instability indicate therapeutic sensitivities in high-grade serous ovarian carcinoma.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-19-0852.
    PubMed     Abstract available


  13. HUANG TT, Brill E, Nair JR, Zhang X, et al
    Targeting the PI3K/mTOR pathway augments CHK1 inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cance.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-20-1439.
    PubMed     Abstract available


  14. AZAR WJ, Christie EL, Mitchell C, Liu DS, et al
    Non-canonical IL-6 signaling-mediated activation of YAP regulates cell migration and invasion in ovarian clear cell cancer.
    Cancer Res. 2020 Sep 11. pii: 0008-5472.CAN-19-3044.
    PubMed     Abstract available


  15. CARLES A, Trigo-Gonzalez G, Cao Q, Cheng SG, et al
    The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity.
    Cancer Res. 2020;80:3480-3491.
    PubMed     Abstract available


  16. WEIS-BANKE SE, Lerdrup M, Kleine-Kohlbrecher D, Mohammad F, et al
    Mutant FOXL2(C134W) Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors.
    Cancer Res. 2020;80:3466-3479.
    PubMed     Abstract available


  17. TUBEUF H, Caputo SM, Sullivan T, Rondeaux J, et al
    Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System.
    Cancer Res. 2020;80:3593-3605.
    PubMed     Abstract available


    August 2020
  18. ZONG X, Wang W, Ozes A, Fang F, et al
    EZH2-mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
    Cancer Res. 2020 Aug 19. pii: 0008-5472.CAN-20-0458.
    PubMed     Abstract available


  19. GEISTLINGER L, Oh S, Ramos M, Schiffer L, et al
    Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma.
    Cancer Res. 2020 Aug 3. pii: 0008-5472.CAN-20-0521.
    PubMed     Abstract available


  20. PALMER AC, Plana D, Gao H, Korn JM, et al
    A proof of concept for biomarker-guided targeted therapy against ovarian cancer based on patient-derived tumor xenografts.
    Cancer Res. 2020 Aug 3. pii: 0008-5472.CAN-19-3850.
    PubMed     Abstract available


    July 2020
  21. MATSUI T, Tamoto R, Iwasa A, Mimura M, et al
    Nonlinear optics with near-infrared excitation enable real-time quantitative diagnosis of human cervical cancers.
    Cancer Res. 2020 Jul 23. pii: 0008-5472.CAN-20-0348.
    PubMed     Abstract available


  22. ASARE-WEREHENE M, Communal L, Carmona E, Han Y, et al
    Plasma gelsolin inhibits CD8+ T cell function and regulates glutathione production to confer chemoresistance in ovarian cancer.
    Cancer Res. 2020 Jul 8. pii: 0008-5472.CAN-20-0788.
    PubMed     Abstract available


  23. LOU H, Boland JF, Torres-Gonzalez E, Albanez A, et al
    The D2 and D3 sublineages of human papillomavirus 16-positive cervical cancer in Guatemala differ in integration rate and age of diagnosis.
    Cancer Res. 2020 Jul 6. pii: 0008-5472.CAN-20-0029.
    PubMed     Abstract available


  24. GRIESSINGER CM, Olafsen T, Mascioni A, Jiang ZK, et al
    The PET-Tracer (89)Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment.
    Cancer Res. 2020;80:2903-2913.
    PubMed     Abstract available


    June 2020
  25. HUANG H, Wang Y, Kandpal M, Zhao G, et al
    FTO-Dependent N6-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling.
    Cancer Res. 2020 Jun 30. pii: 0008-5472.CAN-19-4044.
    PubMed     Abstract available


  26. HILLESTAD T, Hompland T, Fjeldbo CS, Skingen VE, et al
    MR Imaging Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer.
    Cancer Res. 2020 Jun 30. pii: 0008-5472.CAN-20-0950.
    PubMed     Abstract available


    May 2020
  27. MATEI D, Nephew KP
    Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes.
    Cancer Res. 2020 May 7. pii: 0008-5472.CAN-19-3837.
    PubMed     Abstract available


    April 2020
  28. PARK Y, Pang K, Park J, Hong E, et al
    Destabilization of TRAF6 by DRAK1 suppresses tumor growth and metastasis in cervical cancer cells.
    Cancer Res. 2020 Apr 7. pii: 0008-5472.CAN-19-3428.
    PubMed     Abstract available


  29. MEULEMANS L, Mesman RLS, Caputo SM, Krieger S, et al
    Skipping Nonsense to Maintain Function: The Paradigm of BRCA2 Exon 12.
    Cancer Res. 2020;80:1374-1386.
    PubMed     Abstract available


    February 2020
  30. MCCOOL KW, Freeman ZT, Zhai Y, Wu R, et al
    Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    Cancer Res. 2020;80:877-889.
    PubMed     Abstract available


  31. MUKHERJEE A, Chiang CY, Daifotis HA, Nieman KM, et al
    Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance.
    Cancer Res. 2020 Feb 13. pii: 0008-5472.CAN-19-1999.
    PubMed     Abstract available


  32. RODRIGUEZ AC, Vahrenkamp JM, Berrett KC, Clark KA, et al
    ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells.
    Cancer Res. 2020 Feb 11. pii: 0008-5472.CAN-19-1382.
    PubMed     Abstract available


    January 2020
  33. ZELEZNIK OA, Eliassen AH, Kraft P, Poole EM, et al
    A prospective analysis of circulating plasma metabolites associated with ovarian cancer risk.
    Cancer Res. 2020 Jan 22. pii: 0008-5472.CAN-19-2567.
    PubMed     Abstract available


  34. TRABERT B, Tworoger SS, O'Brien KM, Townsend MK, et al
    The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the Ovarian Cancer Cohort Consortium (OC3).
    Cancer Res. 2020 Jan 13. pii: 0008-5472.CAN-19-2850.
    PubMed     Abstract available


  35. ASEM M, Young AM, Oyama C, Claure De La Zerda AG, et al
    Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis.
    Cancer Res. 2020 Jan 13. pii: 0008-5472.CAN-19-1601.
    PubMed     Abstract available


    December 2019
  36. NACARELLI T, Fukumoto T, Zundell JA, Fatkhutdinov N, et al
    NAMPT inhibition suppresses cancer stem-like cells associated with therapy-induced senescence in ovarian cancer.
    Cancer Res. 2019 Dec 19. pii: 0008-5472.CAN-19-2830.
    PubMed     Abstract available


  37. MOYER CL, Ivanovich J, Gillespie JL, Doberstein R, et al
    Rare BRIP1 missense alleles confer risk for ovarian and breast cancer.
    Cancer Res. 2019 Dec 10. pii: 0008-5472.CAN-19-1991.
    PubMed     Abstract available


    November 2019
  38. LI C, Course MM, McNeish IA, Drescher CW, et al
    Prophylactic in vivo hematopoietic stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models.
    Cancer Res. 2019 Nov 14. pii: 0008-5472.CAN-19-1044.
    PubMed     Abstract available


    October 2019
  39. KANAKKANTHARA A, Kurmi K, Ekstrom TL, Hou X, et al
    BRCA1 Deficiency Upregulates NNMT Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
    Cancer Res. 2019 Oct 16. pii: 0008-5472.CAN-19-1405.
    PubMed     Abstract available


  40. CARBONE M, Melino G
    Stearoyl CoA Desaturase Regulates Ferroptosis in Ovarian Cancer Offering New Therapeutic Perspectives.
    Cancer Res. 2019;79:5149-5150.
    PubMed     Abstract available


    September 2019
  41. CHUI MH, Doodnauth SA, Erdmann N, Tiedemann RE, et al
    Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma.
    Cancer Res. 2019 Sep 17. pii: 0008-5472.CAN-18-3029.
    PubMed     Abstract available


  42. ROBERTS AL, Huang T, Koenen KC, Kim Y, et al
    Posttraumatic stress disorder (PTSD) is associated with increased risk of ovarian cancer: a prospective and retrospective longitudinal cohort study.
    Cancer Res. 2019 Sep 5. pii: 0008-5472.CAN-19-1222.
    PubMed     Abstract available


    August 2019
  43. PERES LC, Mallen AR, Townsend MK, Poole EM, et al
    High levels of C-reactive protein are associated with an increased risk of ovarian cancer: Results from the Ovarian Cancer Cohort Consortium.
    Cancer Res. 2019 Aug 28. pii: 0008-5472.CAN-19-1554.
    PubMed     Abstract available


  44. HAINES K, Huang GS
    Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A.
    Cancer Res. 2019;79:4009-4010.
    PubMed     Abstract available


    July 2019
  45. SHANG S, Yang J, Jazaeri AA, Duval AJ, et al
    Chemotherapy-induced distal enhancers drive transcriptional program to maintain the chemoresistant state in ovarian cancer.
    Cancer Res. 2019 Jul 29. pii: 0008-5472.CAN-19-0215.
    PubMed     Abstract available


  46. FUKUMOTO T, Fatkhutdinov N, Zundell JA, Tcyganov EN, et al
    HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.
    Cancer Res. 2019 Jul 16. pii: 0008-5472.CAN-19-1302.
    PubMed     Abstract available


  47. ARROYO-MUHR LS, Lagheden C, Hultin E, Eklund C, et al
    The HPV16 genome is stable in women who progress to in situ or invasive cervical cancer: a prospective population-based study.
    Cancer Res. 2019 Jul 9. pii: 0008-5472.CAN-18-3933.
    PubMed     Abstract available


  48. TESFAY L, Paul BT, Konstorum A, Deng Z, et al
    Steroyl-CoA Desaturase 1 (SCD1) protects ovarian cancer cells from ferroptotic cell death.
    Cancer Res. 2019 Jul 3. pii: 0008-5472.CAN-19-0369.
    PubMed     Abstract available


    June 2019
  49. LU D, Andrae B, Valdimarsdottir U, Sundstrom K, et al
    Psychological distress is associated with cancer-specific mortality among patients with cervical cancer.
    Cancer Res. 2019 Jun 28. pii: 0008-5472.CAN-19-0116.
    PubMed     Abstract available


  50. LEE H, Oh Y, Jeon YJ, Lee SY, et al
    DR4-Ser424 O-GlcNAcylation Promotes Sensitization of TRAIL-Tolerant Persisters and TRAIL-Resistant Cancer Cells to Death.
    Cancer Res. 2019;79:2839-2852.
    PubMed     Abstract available


  51. FUKUMOTO T, Zhu H, Nacarelli T, Karakashev S, et al
    N(6)-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance.
    Cancer Res. 2019;79:2812-2820.
    PubMed     Abstract available


    May 2019
  52. TAYLOR SE, O'Connor CM, Wang Z, Shen G, et al
    The highly recurrent PP2A Aalpha-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis.
    Cancer Res. 2019 May 29. pii: 0008-5472.CAN-19-0218.
    PubMed     Abstract available


  53. MUYS BR, Sousa JF, Placa JR, Araujo LF, et al
    miR-450a acts as a tumor suppressor in ovarian cancer by regulating energy metabolism.
    Cancer Res. 2019 May 17. pii: 0008-5472.CAN-19-0490.
    PubMed     Abstract available


  54. DORAYAPPAN KDP, Gardner ML, Hisey CL, Zingarelli RA, et al
    A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer.
    Cancer Res. 2019 May 16. pii: 0008-5472.CAN-18-3538.
    PubMed     Abstract available


  55. TRAVERS M, Brown SM, Dunworth M, Holbert CE, et al
    DFMO and 5-azacytidine increase M1 macrophages in the tumor microenvironment of murine ovarian cancer.
    Cancer Res. 2019 May 14. pii: 0008-5472.CAN-18-4018.
    PubMed     Abstract available


  56. MUKHERJEE A, Huynh V, Gaines K, Reh WA, et al
    Targeting the High Mobility Group Box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin.
    Cancer Res. 2019 May 6. pii: 0008-5472.CAN-19-0542.
    PubMed     Abstract available


    April 2019
  57. RAMAMOORTHY P, Thomas SM, Kaushik G, Subramaniam D, et al
    Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.
    Cancer Res. 2019;79:1681-1695.
    PubMed     Abstract available


    March 2019
  58. PRICE C, Gill S, Ho ZV, Davidson SM, et al
    Genome-wide interrogation of human cancers identifies EGLN1 dependency in clear cell ovarian cancers.
    Cancer Res. 2019 Mar 21. pii: 0008-5472.CAN-18-2674.
    PubMed     Abstract available


  59. SRIVASTAVA AK, Banerjee A, Cui T, Han C, et al
    Inhibition of miR-328-3p impairs cancer stem cell function and prevents metastasis in ovarian cancer.
    Cancer Res. 2019 Mar 20. pii: 0008-5472.CAN-18-3668.
    PubMed     Abstract available


  60. NATARAJAN S, Foreman KM, Soriano MI, Rossen NS, et al
    Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis.
    Cancer Res. 2019 Mar 12. pii: 0008-5472.CAN-18-2616.
    PubMed     Abstract available


    February 2019
  61. MCCORMICK PN, Greenwood HE, Glaser M, Maddocks ODK, et al
    Assessment of Tumor Redox Status through (S)-4-(3-[(18)F]fluoropropyl)-L-Glutamic Acid PET Imaging of System xc (-) Activity.
    Cancer Res. 2019;79:853-863.
    PubMed     Abstract available


  62. CHOI J, Brown KM
    A Dynamic Cis-Regulation Pattern Underlying Epithelial Ovarian Cancer Susceptibility.
    Cancer Res. 2019;79:439-440.
    PubMed     Abstract available


    January 2019
  63. WALCH-RUCKHEIM B, Stroder R, Theobald L, Pahne-Zeppenfeld J, et al
    Cervical cancer-instructed stromal fibroblasts enhance IL-23 expression in dendritic cells to support expansion of Th17 cells.
    Cancer Res. 2019 Jan 29. pii: 0008-5472.CAN-18-1913.
    PubMed     Abstract available


  64. DYER A, Schoeps B, Frost S, Jakeman P, et al
    Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.
    Cancer Res. 2019;79:331-345.
    PubMed     Abstract available


  65. SHEN J, Zhao W, Ju Z, Wang L, et al
    PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    Cancer Res. 2019;79:311-319.
    PubMed     Abstract available


  66. YAGI A, Ueda Y, Kakuda M, Tanaka Y, et al
    Epidemiological and clinical analyses of cervical cancer using data from the population-based Osaka cancer registry.
    Cancer Res. 2019 Jan 11. pii: 0008-5472.CAN-18-3109.
    PubMed     Abstract available


    December 2018
  67. HOODA J, Novak M, Salomon MP, Matsuba C, et al
    Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer.
    Cancer Res. 2018 Dec 18. pii: 0008-5472.CAN-18-2297.
    PubMed     Abstract available


  68. YANG Y, Wu L, Shu X, Lu Y, et al
    Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk.
    Cancer Res. 2018 Dec 17. pii: 0008-5472.CAN-18-2726.
    PubMed     Abstract available


    November 2018
  69. BUCKLEY MA, Woods NT, Tyrer JP, Mendoza-Fandino G, et al
    Functional analysis and fine mapping of the 9p22.2 ovarian cancer susceptibility locus.
    Cancer Res. 2018 Nov 28. pii: 0008-5472.CAN-17-3864.
    PubMed     Abstract available


  70. POLUSANI SR, Huang YW, Huang G, Chen CW, et al
    Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer.
    Cancer Res. 2018 Nov 2. pii: 0008-5472.CAN-18-1615.
    PubMed     Abstract available


    October 2018

  71. Correction: RSF1 Is a Positive Regulator of NFkappaB-induced Gene Expression Required for Ovarian Cancer Chemoresistance.
    Cancer Res. 2018;78:6024.
    PubMed    


    September 2018
  72. LIU M, Thomas SL, DeWitt AK, Zhou W, et al
    Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells.
    Cancer Res. 2018 Sep 5. pii: 0008-5472.CAN-17-3953.
    PubMed     Abstract available


    August 2018
  73. BYEON Y, Lee JW, Choi WS, Won JE, et al
    CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer.
    Cancer Res. 2018 Aug 16. pii: 0008-5472.CAN-17-3871.
    PubMed     Abstract available



  74. Correction: Significance of MAD2 Expression to Mitotic Checkpoint Control in Ovarian Cancer Cells.
    Cancer Res. 2018;78:4800.
    PubMed    


  75. BELANGER F, Fortier E, Dube M, Lemay JF, et al
    Replication Protein A Availability During DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells.
    Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-18-0618.
    PubMed     Abstract available


    July 2018
  76. LU Y, Beeghly-Fadiel A, Wu L, Guo X, et al
    A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk.
    Cancer Res. 2018 Jul 27. pii: 0008-5472.CAN-18-0951.
    PubMed     Abstract available



  77. Correction: Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma.
    Cancer Res. 2018;78:4100.
    PubMed    



  78. Correction: Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer.
    Cancer Res. 2018;78:4099.
    PubMed    



  79. Correction: FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes.
    Cancer Res. 2018;78:3742.
    PubMed    


    June 2018

  80. Correction: Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.
    Cancer Res. 2018;78:3402.
    PubMed    


  81. HIRST J, Pathak HB, Hyter S, Pessetto ZY, et al
    Licofelone enhances the efficacy of paclitaxel in ovarian cancer by reversing drug resistance and tumor stem-like properties.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-3993.
    PubMed     Abstract available


    May 2018
  82. HAUTANIEMI S, Kozlowska E, Farkkila A, Vallius T, et al
    Mathematical modeling predicts response to chemotherapy and drug combinations in ovarian cancer.
    Cancer Res. 2018 May 16. pii: 0008-5472.CAN-17-3746.
    PubMed     Abstract available


  83. SALEM M, O'Brien JA, Bernaudo S, Shawer H, et al
    miRNA-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-versican pathway.
    Cancer Res. 2018 May 10. pii: 0008-5472.CAN-17-3014.
    PubMed     Abstract available


  84. CARROLL MJ, Fogg KC, Patel HA, Krause HB, et al
    Alternatively activated macrophages upregulate mesothelial expression of P-selectin to enhance adhesion of ovarian cancer cells.
    Cancer Res. 2018 May 8. pii: 0008-5472.CAN-17-3341.
    PubMed     Abstract available


  85. LUO XL, Deng C, Su XD, Wang F, et al
    Loss of MED12 induces tumor dormancy in human epithelial ovarian cancer via downregulation of EGFR.
    Cancer Res. 2018 May 7. pii: 0008-5472.CAN-18-0134.
    PubMed     Abstract available



  86. Correction: Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERalpha in Tamoxifen-Associated Endometrial Carcinomas.
    Cancer Res. 2018;78:2446.
    PubMed    


    April 2018
  87. CASTLE PE
    Charting the Future of Cancer Health Disparities Research-Letter.
    Cancer Res. 2018;78:1883-1885.
    PubMed    


  88. SHARMA SK, Chow A, Monette S, Vivier D, et al
    Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.
    Cancer Res. 2018;78:1820-1832.
    PubMed     Abstract available


  89. SAINI U, Suarez AA, Naidu S, Wallbillich JJ, et al
    STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.
    Cancer Res. 2018;78:1739-1750.
    PubMed     Abstract available


    March 2018
  90. CONDELLO S, Sima LE, Ivan C, Cardenas H, et al
    Tissue transglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche.
    Cancer Res. 2018 Mar 6. pii: 0008-5472.CAN-17-2319.
    PubMed     Abstract available


    January 2018
  91. HA JH, Radhakrishnan R, Jayaraman M, Yan M, et al
    Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response.
    Cancer Res. 2018 Jan 31. pii: 0008-5472.CAN-17-1624.
    PubMed     Abstract available


  92. ZHANG Y, Li L, Wang L, Li J, et al
    Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer.
    Cancer Res. 2018 Jan 26. pii: 0008-5472.CAN-17-2460.
    PubMed     Abstract available


  93. CURRY E, Zeller C, Masrour N, Patten D, et al
    Genes predisposed to DNA hypermethylation during acquired resistance to chemotherapy are identified in ovarian tumors by bivalent chromatin domains at initial diagnosis.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-1650.
    PubMed     Abstract available


  94. RASHMI R, Huang X, Floberg JM, Elhammali A, et al
    Radio-resistant Cervical Cancers Are Sensitive to Inhibition of Glycolysis and Redox Metabolism.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-2367.
    PubMed     Abstract available


  95. LU Y, Hu Z, Mangala LS, Stine ZE, et al
    MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.
    Cancer Res. 2018;78:64-74.
    PubMed     Abstract available


    December 2017
  96. KANG J, Shin SH, Yoon H, Huh J, et al
    FIH is an oxygen sensor in ovarian cancer for G9a/GLP-driven epigenetic regulation of metastasis-related genes.
    Cancer Res. 2017 Dec 19. pii: 0008-5472.CAN-17-2506.
    PubMed     Abstract available


  97. SHANG C, Wang W, Liao Y, Chen Y, et al
    LNMICC promotes nodal metastasis of cervical cancer by reprogramming fatty acid metabolism.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-2356.
    PubMed     Abstract available


  98. FANG F, Cardenas H, Huang H, Jiang G, et al
    Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Re-sensitization to Platinum Drugs.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1492.
    PubMed     Abstract available


    November 2017
  99. HIRAMATSU K, Serada S, Enomoto T, Takahashi Y, et al
    LSR antibody therapy inhibits ovarian epithelial tumor growth by inhibiting lipid uptake.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0910.
    PubMed     Abstract available


    October 2017
  100. HOUSE CD, Jordan E, Hernandez L, Ozaki M, et al
    NF-kB promotes ovarian tumorigenesis via classical pathways supporting proliferative cancer cells and alternative pathways supporting ALDH+ cancer stem-like cells.
    Cancer Res. 2017 Oct 26. pii: canres.0366.2017.
    PubMed     Abstract available


  101. WU X, Serna VA, Thomas J, Qiang W, et al
    Subtype-specific cancer-associated fibroblasts contribute to the pathogenesis of uterine leiomyoma.
    Cancer Res. 2017 Oct 20. pii: canres.1744.2017.
    PubMed     Abstract available


  102. PAYEN VL, Hsu MY, Radecke KS, Wyart E, et al
    Monocarboxylate Transporter MCT1 Promotes Tumor Metastasis Independently of Its Activity as a Lactate Transporter.
    Cancer Res. 2017;77:5591-5601.
    PubMed     Abstract available


  103. CICHOCKI F, Valamehr B, Bjordahl R, Zhang B, et al
    GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
    Cancer Res. 2017;77:5664-5675.
    PubMed     Abstract available


  104. LAMICHHANE P, Karyampudi L, Shreeder B, Krempski J, et al
    IL-10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer.
    Cancer Res. 2017 Oct 9. pii: canres.0740.2017.
    PubMed     Abstract available


  105. GALL VA, Philips AV, Qiao N, Clise-Dwyer K, et al
    Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
    Cancer Res. 2017;77:5374-5383.
    PubMed     Abstract available


    September 2017
  106. YIN X, Jing Y, Cai MC, Ma P, et al
    Clonality, heterogeneity and evolution of synchronous bilateral ovarian cancer.
    Cancer Res. 2017 Sep 28. pii: canres.1461.2017.
    PubMed     Abstract available


  107. FALCETTA F, Bizzaro F, D'Agostini E, Bani MR, et al
    Modeling cytostatic and cytotoxic responses to new treatment regimens for ovarian cancer.
    Cancer Res. 2017 Sep 26. pii: canres.1099.2017.
    PubMed     Abstract available



  108. Retraction: CYP1B1 Gene Polymorphisms Have Higher Risk for Endometrial Cancer, and Positive Correlations with Estrogen Receptor alpha and Estrogen Receptor beta Expressions.
    Cancer Res. 2017;77:5211.
    PubMed    


  109. SONG KH, Choi CH, Lee HJ, Oh SJ, et al
    HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.
    Cancer Res. 2017;77:5039-5053.
    PubMed     Abstract available


    July 2017
  110. PIACENTE F, Caffa I, Ravera S, Sociali G, et al
    Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Cancer Res. 2017;77:3857-3869.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: